Newsroom

Dr. Peter Sullivan in the lab.
Interview
A key focus at the Helmholtz Centre for Infection Research (HZI) and its sites like the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) is translating research findings into medical and pharmaceutical applications. Beyond scientific collaboration, the goal is to facilitate the transfer of technology and knowledge into practical and potentially commercial uses. Recently, the company MyxoTech has been founded as a HIPS spin-off. MyxoTech CEO Peter Sullivan explains what the new company is about and what it wants to achieve.
29.08.2024
Group photo 4 scientists with a large cheque
News
Yesterday, the lighthouse project of the state of Lower Saxony reached its latest milestone: At the second portfolio conference of the Institute for Biomedical Translation (IBT) Lower Saxony, a high-caliber jury selected projects from the Helmholtz Centre for Infection Research and the Hannover Medical School that will receive funding of over 1.6 million euros. A total of 25 million euros are available to the IBT Lower Saxony until 2028 to accelerate the transfer of cutting-edge research in the life sciences in Lower Saxony and to bring it out into the world in the form of startups and entrepreneurial ideas.
28.08.2024
Marco Galardini (left) and Maureen Obara in the lab.
News
Certain changes in the genetic material of pathogens can alter their ability to infect human cells or protect them better from defense by the immune system. Researchers were able to observe this effect particularly impressive in the SARS-CoV-2 virus. During the coronavirus pandemic, an interdisciplinary team at TWINCORE, Centre for Experimental and Clinical Infection Research in Hanover, investigated the interaction between pairs of mutations that might have triggered several of these changes in infectivity and immune escape. They have now published their findings in the journal Genome Biology. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH).
23.08.2024
Interview
The current outbreak of the Mpox virus originated in Central Africa. A first case has now been discovered in Europe. The WHO has declared the highest alert level. In an interview with Helmholtz, Fabian Leendertz, Director of the Helmholtz Institute for One Health (HIOH), puts the events in context.
23.08.2024
3D illustration of the cytomegalovirus
News
The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine hesitation. In contrast, an innovative vector vaccine developed at the Helmholtz Centre for Infection Research (HZI) presents a compelling alternative. It elicits prolonged immune response in animal models, and maintains its efficacy over extended time. The concept employs an animal cytomegalovirus (MCMV; murine cytomegalovirus) as the vector that expresses and delivers the coronavirus spike protein information. Crucially, this vector poses no threat to humans, enhancing the vaccine's safety profile.
20.08.2024
Preview of sCIRCLE
News
Modern cutting-edge research generates enormous amounts of data, presenting scientists with the challenge of visualizing and analyzing it. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the Technical University of Applied Sciences Würzburg-Schweinfurt (THWS) have developed a tool for visualizing large data sets. The sCIRCLE tool allows users to explore single-cell analysis data in an interactive and user-friendly way. Their results have been published in the journal NAR Genomics and Bioinformatics.
30.07.2024

HZI in the media

Mikrobiologen auch Kolleg*innen vom IST Austria und dem HZI in Braunschweig gehören: Inhibitoren von Aktin unterbinden diese dynamischen

01.10.2026
|
Science.apa.at

... der Medizinischen Hochschule Hannover sowie am Helmholtz-Zentrum für Infektionsforschung tätig ist. Als Co-Autor ist zudem ...

30.09.2026
|
Ad Hoc News

also included Japanese microbiologists and collaborators from IST Austria and HZI Braunschweig (Germany), demonstrated that actin inhibitors

30.09.2026
|
Phys.org

for cell movement. Scientists from the Helmholtz Center for Infection Research (HZI) in Braunschweig have provided evidence that Profilin

29.09.2026
|
TakeToNews

Biology (BRICS), a joint research center of the Helmholtz Centre for Infection Research (HZI) and Technische Universität Braunschweig.

29.09.2026
|
Phys.org

... treffsicher .

 

Das Helmholtz-Zentrum für Infektionsforschung:

 

Wissenschaftler:innen am Helmholtz-Zentrum für Infektionsforschung (HZI) ...

28.09.2026
|
DeutschesGesundheitsPortal

... Fluorchinolon-Resistenz aktiv

 

Forscher des Helmholtz-Zentrums für Infektionsforschung (HZI) um Dr. Jennifer Herrmann haben ...

27.09.2026
|
scinexx - Das Wissensmagazin

Die WHO nennt Antibiotikaresistenzen (AMR) eine der größten globalen Gesundheitsbedrohungen. Bereits heute töten resistente Keime jährlich mehr als eine Million Menschen direkt und tragen zu fast fünf Millionen Todesfällen bei. Tendenz: steigend. Für ein wirkungsvolles Dagegenha

25.09.2026
|
Sysmex

... die Resistenzen": HZI-Podcast InFact mit Mark Brönstrup

 

Quelle: Helmholtz-Zentrum für Infektionsforschung (HZI)

 

Biodiversität ...

25.09.2026
|
Analytik NEWS

Quelle: Pressemitteilung

 

Helmholtz-Zentrum für Infektionsforschung

24.09.2026
|
LaborPraxis

Lange galt Dopamin als simples Glückshormon. Alena Buyx zeigt in ihrer Sendung, dass der Botenstoff ...

24.09.2026
|
3sat

Leibniz-Lungenzentrum. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit der Universität ...

23.09.2026
|
DeutschesGesundheitsPortal

Register now for the HZI newsletter